News Archive

13 May 2015

Merck Animal Health Announces Expanded ZUPREVO® (tildipirosin) Label in EU to Include Metaphylactic Use in Swine

Now indicated for use in piglets of all ages

MADISON, N.J., May 13, 2015 – Merck Animal Health (known as MSD Animal Health outside the United States and Canada) today announced the expansion of the ZUPREVO® (tildipirosin) label following approval from the Committee for Medicinal Products for Veterinary Use (CVMP) of the European Medicines.

The label for ZUPREVO® (tildiprosin), a broad spectrum antibiotic for the treatment of Swine Respiratory Disease (SRD) associated with  Actinobacillus pleuropneumoniae, Pasteurella multocida, Bordetella bronchiseptica  and  Haemophilus parasuis,will now include m etaphylactic use which allows clinically-healthy (but presumably infected) or susceptible animals in close contact with diseased animals to be treated to reduce the risk for developing clinical disease. In addition, age restrictions have been removed, allowing ZUPREVO to now be used in piglets of all ages.

“ZUPREVO is an important tool in the fight against SRD, offering long-acting protection against four major pathogens associated with this disease with just one injection,” said Olivia Azlor, Merck Animal Health. “We are pleased to announce these new label changes, which will help veterinarians and producers extend their protection against these costly diseases by reducing the risk for disease spread, and applying earlier treatment to avoid bigger problems and losses.”

SRD often comes along with reduced feed efficiency and growth, making it a major economic concern in pig farms around the world. A number of factors can contribute to SRD, and it seldom results from only one pathogen. Strict management policies and monitoring must be implemented to control the disease and avoid spread of pathogens within herds.

About Merck Animal Health
Today's Merck is a global healthcare leader working to help the world be well. Merck Animal Health, known as MSD Animal Health outside the United States and Canada, is the global animal health business unit of Merck. Through its commitment to the Science of Healthier Animals™, Merck Animal Health offers veterinarians, farmers, pet owners and governments one of the widest range of veterinary pharmaceuticals, vaccines and health management solutions and services. Merck Animal Health is dedicated to preserving and improving the health, well-being and performance of animals. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. Merck Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit www.merck-animal-health.com  or connect with us on LinkedIn and Twitter at @MerckAH.

Merck forward-Looking Statement
This news release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of Merck’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Merck’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Merck’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in Merck’s 2014 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site ( www.sec.gov ).